Abstract
The Transforming Growth Factor-β (TGFβ) superfamily of cytokines is comprised of a number of structurally-related, secreted polypeptides that regulate a multitude of cellular processes including proliferation, differentiation and neoplastic transformation. These growth regulatory molecules induce ligandmediated hetero-oligomerization of distinct type II and type I serine / threonine kinase receptors that transmit signals predominantly through receptor-activated Smad proteins but also induce Smad-independent pathways. Ligands, receptors and intracellular mediators of signaling initiated by members of the TGFβ family are expressed in the mammary gland and disruption of these pathways may contribute to the development and progression of human breast cancer. Since many facets of TGFβ and breast cancer have been recently reviewed in several articles, except for discussion of recent developments on some aspects of TGFβ, the major focus of this review will be on the role of activins, inhibins, BMPs, nodal and MIS-signaling in breast cancer with emphasis on their utility as potential diagnostic, prognostic and therapeutic targets.
Keywords: proteins, hetero-oligomerization
Current Cancer Drug Targets
Title: Transforming Growth Factor-β Superfamily: Evaluation as Breast Cancer Biomarkers and Preventive Agents
Volume: 4 Issue: 2
Author(s): V. Gupta, D. P. Harkin, H. Kawakubo and S. Maheswaran
Affiliation:
Keywords: proteins, hetero-oligomerization
Abstract: The Transforming Growth Factor-β (TGFβ) superfamily of cytokines is comprised of a number of structurally-related, secreted polypeptides that regulate a multitude of cellular processes including proliferation, differentiation and neoplastic transformation. These growth regulatory molecules induce ligandmediated hetero-oligomerization of distinct type II and type I serine / threonine kinase receptors that transmit signals predominantly through receptor-activated Smad proteins but also induce Smad-independent pathways. Ligands, receptors and intracellular mediators of signaling initiated by members of the TGFβ family are expressed in the mammary gland and disruption of these pathways may contribute to the development and progression of human breast cancer. Since many facets of TGFβ and breast cancer have been recently reviewed in several articles, except for discussion of recent developments on some aspects of TGFβ, the major focus of this review will be on the role of activins, inhibins, BMPs, nodal and MIS-signaling in breast cancer with emphasis on their utility as potential diagnostic, prognostic and therapeutic targets.
Export Options
About this article
Cite this article as:
Gupta V., Harkin P. D., Kawakubo H. and Maheswaran S., Transforming Growth Factor-β Superfamily: Evaluation as Breast Cancer Biomarkers and Preventive Agents, Current Cancer Drug Targets 2004; 4 (2) . https://dx.doi.org/10.2174/1568009043481542
DOI https://dx.doi.org/10.2174/1568009043481542 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Case of Neurosarcoidosis Mimicking Brain Tumor
Current Medical Imaging The Role of ING Tumor Suppressors in UV Stress Response and Melanoma Progression
Current Drug Targets From Nanotechnology to Nanomedicine: Applications to Cancer Research
Current Molecular Medicine Recent Advances in Liposomal Drug Delivery: A Review
Pharmaceutical Nanotechnology Monoclonal Antibodies as Innovative Therapeutics
Current Pharmaceutical Biotechnology Pharmacophore Modeling for Antitargets
Current Topics in Medicinal Chemistry Management of Chemotherapy Induced Cardiomyopathy
Current Cardiology Reviews Current Evidence and Potential Mechanisms of Therapeutic Action of PEDF in Cervical Cancer Treatment
Current Molecular Medicine Nutlins and Ionizing Radiation in Cancer Therapy
Current Pharmaceutical Design Tubulin Inhibitors: A Patent Survey
Recent Patents on Anti-Cancer Drug Discovery Editorial: Neuronanomedicine - (Part II)
Current Medicinal Chemistry Liposomes: An Emerging Approach for the Treatment of Cancer
Current Pharmaceutical Design Content Analysis, Cytotoxic, and Anti-metastasis Potential of Bioactive Polysaccharides from Green Alga <i>Codium intricatum</i> Okamura
Current Bioactive Compounds Seq and You Will Find
Current Gene Therapy System Models, Assays and Endpoint Parameters to Evaluate Anticancer Compounds During Preclinical Screening
Current Medicinal Chemistry MDM2 Increases Drug Resistance in Cancer Cells by Inducing EMT Independent of p53
Current Medicinal Chemistry Emerging Role of ImmunoPET in Receptor Targeted Cancer Therapy
Current Drug Delivery Interaction Between Arsenic Trioxide and Human Primary Cells: Emphasis on Human Cells of Myeloid Origin
Inflammation & Allergy - Drug Targets (Discontinued) The Effects of Bisphosphonates on the Bone Marrow Niche and Circulating and Disseminated Tumor Cells
Current Cancer Therapy Reviews Dynamic Localization of Hepatocellular Transporters: Role in Biliary Excretion and Impairment in Cholestasis
Current Medicinal Chemistry